ANCHIANO THERAP/S (NASDAQ:ANCN) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $6.73 and last traded at $7.47, with a volume of 200 shares changing hands. The stock had previously closed at $7.56.
Several research firms recently commented on ANCN. Oppenheimer assumed coverage on shares of ANCHIANO THERAP/S in a report on Monday. They issued an “outperform” rating and a $16.00 price target on the stock. LADENBURG THALM/SH SH assumed coverage on shares of ANCHIANO THERAP/S in a research report on Monday. They issued a “buy” rating for the company.
ANCHIANO THERAP/S Company Profile (NASDAQ:ANCN)
Anchiano Therapeutics Ltd, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to treat cancer-related diseases. It is primarily developing Inodiftagene vixteplasmid for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Read More: Buy-Side Analysts
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.